Compare VMD & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VMD | CRDF |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 313.3M | 130.7M |
| IPO Year | 2018 | 2012 |
| Metric | VMD | CRDF |
|---|---|---|
| Price | $9.28 | $2.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.63 |
| AVG Volume (30 Days) | 189.1K | ★ 678.6K |
| Earning Date | 06-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.14 | 27.37 |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $270,280,000.00 | $365,993.00 |
| Revenue This Year | $22.48 | N/A |
| Revenue Next Year | $22.28 | N/A |
| P/E Ratio | $23.68 | ★ N/A |
| Revenue Growth | 20.52 | ★ 49.61 |
| 52 Week Low | $5.93 | $1.48 |
| 52 Week High | $9.20 | $4.56 |
| Indicator | VMD | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 67.08 | 54.74 |
| Support Level | $8.05 | $1.99 |
| Resistance Level | N/A | $2.05 |
| Average True Range (ATR) | 0.35 | 0.13 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 99.39 | 92.08 |
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.